To overcome these limitations, we could collect more patients with germline BRCA1 mutations in the future to perform multi-omics single-cell sequencing and determine early-stage events of ovarian cancer in BRCA1 carriers. The gene discussed is BRCA1; the disease is ovarian carcinoma.